Dimitry Chistiakov

Prof. Dimitry Chistiakov

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
DCDimitry Chistiakov
Dimitry Chistiakov
AOAlexander N. Orekhov
Alexander N. Orekhov
YBYuri Bobryshev
Yuri Bobryshev

Verified
Journal Article
Open access
PDF file
DCDimitry Chistiakov
Dimitry Chistiakov
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
YBYuri Bobryshev
Yuri Bobryshev
Heart is a complex assembly of many cell types constituting myocardium, endocardium and epicardium that intensively communicate to each other in order to maintain the proper cardiac function. There are many types of intercellular intracardiac signals, with a prominent role of extracellular vesicles (EVs), such as exosomes and microvesicles, for long-distant delivering of complex messages. Cardiomyocytes release EVs, whose content could significantly vary depending on the stimulus. In stress, such as hypoxia, inflammation or injury, cardiomyocytes increase secretion of EVs. In hypoxic conditions, cardiac EVs are enriched with angiogenic and prosurvival factors. In acute myocardial infarction (AMI), damaged cardiac muscle cells produce EVs with increased content of angiogenic, anti-apoptotic, mitogenic and growth factors in order to induce repair and healing of the infarcted myocardium. Exosomal microRNAs play a central role in cardiac regeneration. In AMI, circulating cardiac EVs abundantly contain cardiac-specific miRNAs that serve as indicators of cardiac damage and have a big diagnostic potential as AMI biomarkers. Cardioprotective and regenerative properties of exosomes derived from cardiac and non-cardiac stem/progenitor cells are very helpful to be used in cell-free cardiotherapy and regeneration of post-infarct myocardium.

13 October 2011 in Journal of Applied Genetics
Verified
Journal Article
Closed access
PDF file
KPKonstantin Pavlov
Konstantin Pavlov
DCDimitry Chistiakov
Dimitry Chistiakov
VCVladimir Chehonin
Vladimir Chehonin

1 September 2017 in European Journal of Pharmacology
Verified
Journal Article
Closed access
DCDimitry Chistiakov
Dimitry Chistiakov
ICIvan V. Chekhonin
Ivan V. Chekhonin
VCVladimir Chehonin
Vladimir Chehonin

1 June 2015 in Immunobiology
Verified
Journal Article
Closed access
DCDimitry Chistiakov
Dimitry Chistiakov
ISIgor Sobenin
Igor Sobenin
AOAlexander N. Orekhov
Alexander N. Orekhov
YBYuri Bobryshev
Yuri Bobryshev

Verified
Journal Article
Open access
PDF file
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
YBYuri Bobryshev
Yuri Bobryshev
ISIgor Sobenin
Igor Sobenin
AMAlexandra A. Melnichenko
Alexandra A. Melnichenko
DCDimitry Chistiakov
Dimitry Chistiakov
In atherosclerosis; blood low-density lipoproteins (LDL) are subjected to multiple enzymatic and non-enzymatic modifications that increase their atherogenicity and induce immunogenicity. Modified LDL are capable of inducing vascular inflammation through activation of innate immunity; thus, contributing to the progression of atherogenesis. The immunogenicity of modified LDL results in induction of self-antibodies specific to a certain type of modified LDL. The antibodies react with modified LDL forming circulating immune complexes. Circulating immune complexes exhibit prominent immunomodulatory properties that influence atherosclerotic inflammation. Compared to freely circulating modified LDL; modified LDL associated with the immune complexes have a more robust atherogenic and proinflammatory potential. Various lipid components of the immune complexes may serve not only as diagnostic but also as essential predictive markers of cardiovascular events in atherosclerosis. Accumulating evidence indicates that LDL-containing immune complexes can also serve as biomarker for macrovascular disease in type 1 diabetes.